Chapters

Transcript

Video

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)

Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472


Published

February 19, 2021

Created by

Dana-Farber

Related Presenters

Guru P. Sonpavde, MD

Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD is the Bladder Cancer Director at Dana Farber Cancer Institute.

View full Profile